Expertise in
12
conditions

Antonio G. Ruggiero

Rome, IT 
Expertise in
12
conditions
Rome, IT 

Overview

Antonio Ruggiero practices practicing medicine in Rome, Italy.

Mr. Ruggiero is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Diencephalic Syndrome, Gliomatosis Cerebri, Glioma, Optic Glioma, and Splenectomy.

He is actively involved in clinical research, co-authoring 178 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Rome, Italy
Other Locations
Pavia, Italy
Sacro Cuore, 00168, Italy
Milan, Italy
Macerata, Italy
Via Dei Vestini 31, Chieti, 66100, Italy
Porto Potenza Picena, 62018, Italy
Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
Enrollment Status: Completed
Publish Date: March 02, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Irinotecan, Temozolomide
Study Phase: Phase 1/Phase 2

178 Total Publications

Long-term outcomes after a randomized phase II trial of nerve growth factor eye drops for optic pathway gliomas: four-year follow-up findings in children.
Long-term outcomes after a randomized phase II trial of nerve growth factor eye drops for optic pathway gliomas: four-year follow-up findings in children.
Journal: Journal of neuro-oncology
Published: July 24, 2026

Frequently Asked Questions about Antonio G. Ruggiero

Is Antonio G. Ruggiero a top-rated expert for Diencephalic Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Antonio G. Ruggiero is classified as an Distinguished expert for Diencephalic Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Antonio G. Ruggiero participate in research or clinical trials?

Yes. Antonio G. Ruggiero has published 178 articles and abstracts on conditions like Diencephalic Syndrome. You can view a list of Antonio G. Ruggiero's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ruggiero's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 59 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile